Blog Review Us Online

YOU CAN ELIMINATE GLASSES WITH CATARACT SURGERY

YOU CAN ELIMINATE GLASSES WITH CATARACT SURGERY

Would you like to decrease your dependency on glasses or contact lenses? This is now an option with the use of premium lifestyle lens implants. Individuals suffering from cataracts previously had only a monofocal lens implant option after surgery. NEW multifocal IOL technology provides multiple ranges of vision: near, intermediate and far, giving you the opportunity to reduce or even eliminate your dependency on glasses!

YOU CAN ELIMINATE GLASSES WITH CATARACT SURGERY

NEW TECHNIQUES IN TREATING MACULAR DEGENERATION

NEW TECHNIQUES IN TREATING MACULAR DEGENERATION

Did you know there is now advanced testing available for diagnosing macular degeneration?  Macular Risk® is a DNA test that identifies genetic markers associated with Macular Degeneration.  By analyzing these genetic markers along with smoking history, we can identify who needs more frequent eye examinations and who may benefit from eye vitamins. 

NEW TECHNIQUES IN TREATING MACULAR DEGENERATION

TAKE THE VISION CORRECTION SELF TEST

TAKE THE VISION CORRECTION SELF TEST

Are you seeking clear vision without the hassles of glasses or contact lenses? There are many vision correction options available at Kaufman Eye Institute. Take our Vision Correction Self Test to learn what options are best for you!

TAKE THE VISION CORRECTION SELF TEST

MEDICAL MISSIONS

MEDICAL MISSIONS

The physicians and staff at the Kaufman Eye Institute take great pride in helping less fortunate countries receive the eye care that is much needed. Click here to learn about our most recent medical mission.

MEDICAL MISSIONS

Innovations in Macular Degeneration

75% of AMD is caused by genetic changes inherited from one’s parents. Do you know your genetic risk for developing advanced Age Related Macular Degeneration?

Now you can be screened with RetinaGene®.

What is RetinaGene®?

RetinaGene® is a DNA test that identifies genetic markers associated with Macular Degeneration. By analyzing these genetic markers along with smoking history, we can identify who needs more frequent eye examinations and who may benefit from eye vitamins.

Why is this important?

More frequent eye exams increases the chance of early detection, leading to early treatment that can prevent blindness from wet macular degeneration. Data demonstrates that the best outcomes occur when drugs are administered early while the disease is small and outside the fovea, the most sensitive part of the macula.

How is RetinaGene® testing performed?

A simple and painless cheek swab is used to collect the sample in the office. No food or coffee should be ingested for 30 minutes before collection.

Who can have this test?

It is recommended that screening is performed on patients 65 years or older with a diagnosis of early or intermediate AMD. You must have your eyes examined first to know!

Is it covered by insurance?

Yes, Medicare and most insurance providers covers the genetic testing. There is no charge from our office for the DNA testing.

Ask Dr. Lin about this at your next appointment or call 855-SEE-BEST to schedule your examination today.


5/20/2011:

CATT first year results are in!

The Comparison of AMD Treatments Trial (CATT) is a head to head study of Avastin (bevacizumab) vs Lucentis (ranibizumab) funded by the National Eye Institute.  The highly anticipated first year results of the two year study have been released.

Take home points:

Philip J. Rosenfed, MD, Ph.D., the physician who pioneered the use of bevacizumab in AMD patients, comments:

"The CATT results, together with the totality of global experience, support the use of either bevacizumab or ranibizumab for the treatment of neovascular AMD. An as-needed regimen is an acceptable alternative to a monthly regimen, but strict compliance on the part of both the clinician and the patient is required. Health care providers and payers worldwide will now have to justify the cost of using ranibizumab. Regulators in certain countries will be forced to reconsider their policies that make it illegal to use drugs off-label, particularly when so many of their citizens cannot afford ranibizumab. The CATT data support the continued global use of intravitreal bevacizumab as an effective, low-cost alternative to ranibizumab."

Read the full article from the New England Journal of Medicine

My take:

The CATT study reaffirms that both drugs are very good. If a patient is doing well on one there is little reason to change to another.  These results support an individualized approach to treatment. We look forward to the final result of this pivotal study in the following year.

Selina J. Lin, MD